Correlation Between MetaVia and Unicycive Therapeutics

Can any of the company-specific risk be diversified away by investing in both MetaVia and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MetaVia and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between MetaVia and Unicycive Therapeutics, you can compare the effects of market volatilities on MetaVia and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MetaVia with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of MetaVia and Unicycive Therapeutics.

Diversification Opportunities for MetaVia and Unicycive Therapeutics

0.27

Correlation Coefficient

MetaVia  Unicycive Therapeutics

Modest diversification

The 3 months correlation between MetaVia and Unicycive is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding MetaVia and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and MetaVia is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MetaVia are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of MetaVia i.e., MetaVia and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between MetaVia and Unicycive Therapeutics

Given the investment horizon of 90 days MetaVia is expected to under-perform the Unicycive Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, MetaVia is 1.81 times less risky than Unicycive Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Unicycive Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  648.00  in Unicycive Therapeutics on May 5, 2025 and sell it today you would lose (228.00) from holding Unicycive Therapeutics or give up 35.19% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

MetaVia  vs.  Unicycive Therapeutics

MetaVia

Risk-Adjusted Performance

Very Weak

Over the last 90 days MetaVia has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in September 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Unicycive Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Unicycive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in September 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with MetaVia and Unicycive Therapeutics

The main advantage of trading using opposite MetaVia and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MetaVia position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.

The idea behind MetaVia and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.